Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_3
6
86%
Ph not_applicable
1
14%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
6(85.7%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 36 (85.7%)
N/A1 (14.3%)

Trials by Status

completed686%
not_yet_recruiting114%

Recent Activity

0 active trials
Showing 5 of 7
not_yet_recruitingnot_applicable

Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

NCT07480525
completedphase_3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
completedphase_3

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
completedphase_3

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
completedphase_3

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07480525Not Applicable

Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

Not Yet Recruiting
NCT02418585Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Completed
NCT02497287Phase 3

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Completed
NCT03434041Phase 3

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Completed
NCT02493868Phase 3

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Completed
NCT02417064Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Completed
NCT02422186Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7